Phosphodiesterase regulation of nitric oxide signaling.

[1]  D. Kass,et al.  Compartmentalization of Cardiac &bgr;-Adrenergic Inotropy Modulation by Phosphodiesterase Type 5 , 2007 .

[2]  D. Kass,et al.  Acute phosphodiesterase 5 inhibition mimics hemodynamic effects of B-type natriuretic peptide and potentiates B-type natriuretic peptide effects in failing but not normal canine heart. , 2007, Journal of the American College of Cardiology.

[3]  P. Ganz,et al.  Rho Kinase Inhibition Improves Endothelial Function in Human Subjects With Coronary Artery Disease , 2006, Circulation research.

[4]  J. Hare,et al.  Nitroso–Redox Interactions in the Cardiovascular System , 2006, Circulation.

[5]  J. Burnett,et al.  Maximizing the renal cyclic 3'-5'-guanosine monophosphate system with type V phosphodiesterase inhibition and exogenous natriuretic peptide: a novel strategy to improve renal function in experimental overt heart failure. , 2006, Journal of the American Society of Nephrology : JASN.

[6]  G. Lewis,et al.  The emerging role for type 5 phosphodiesterase inhibition in heart failure , 2006, Current heart failure reports.

[7]  G. Lin,et al.  Expression, distribution and regulation of phosphodiesterase 5. , 2006, Current pharmaceutical design.

[8]  Manuela Zaccolo,et al.  Phosphodiesterases and compartmentalized cAMP signalling in the heart. , 2006, European journal of cell biology.

[9]  L. Langeberg,et al.  AKAP signaling complexes: getting to the heart of the matter. , 2006, Trends in molecular medicine.

[10]  D. Cooper,et al.  Cyclic Guanosine Monophosphate Compartmentation in Rat Cardiac Myocytes , 2006, Circulation.

[11]  B. Bennett,et al.  Inhibition of Phosphodiesterase 5 Selectively Reverses Nitrate Tolerance in the Venous Circulation , 2006, Journal of Pharmacology and Experimental Therapeutics.

[12]  O. V. Evgenov,et al.  Inhibition of phosphodiesterase 1 augments the pulmonary vasodilator response to inhaled nitric oxide in awake lambs with acute pulmonary hypertension. , 2006, American journal of physiology. Lung cellular and molecular physiology.

[13]  D. Nagel,et al.  Role of Nuclear Ca2+/Calmodulin-Stimulated Phosphodiesterase 1A in Vascular Smooth Muscle Cell Growth and Survival , 2006, Circulation research.

[14]  J. Liao,et al.  Physiological role of ROCKs in the cardiovascular system. , 2006, American journal of physiology. Cell physiology.

[15]  M. Zaccolo,et al.  Compartmentalized Phosphodiesterase-2 Activity Blunts &bgr;-Adrenergic Cardiac Inotropy via an NO/cGMP-Dependent Pathway , 2006, Circulation research.

[16]  F. Murad,et al.  Proteomic modification by nitric oxide. , 2006, Journal of pharmacological sciences.

[17]  F. Hofmann,et al.  Function of cGMP-dependent protein kinases as revealed by gene deletion. , 2006, Physiological reviews.

[18]  J. Liao,et al.  Rho GTPases, statins, and nitric oxide. , 2005, Circulation research.

[19]  T. Fleming,et al.  Sildenafil citrate therapy for pulmonary arterial hypertension. , 2005, The New England journal of medicine.

[20]  D. Kass,et al.  Sildenafil Inhibits β-Adrenergic–Stimulated Cardiac Contractility in Humans , 2005 .

[21]  J. Corbin,et al.  High lung PDE5: a strong basis for treating pulmonary hypertension with PDE5 inhibitors. , 2005, Biochemical and biophysical research communications.

[22]  G. Angelini,et al.  Effect of sildenafil citrate and a nitric oxide donating sildenafil derivative, NCX 911, on cavernosal relaxation and superoxide formation in hypercholesterolaemic rabbits. , 2005, European journal of pharmacology.

[23]  D. Cooper,et al.  Ca2+-calmodulin-dependent phosphodiesterase (PDE1): current perspectives. , 2005, Cellular signalling.

[24]  K. Nakao,et al.  Calcineurin–Nuclear Factor of Activated T Cells Pathway–Dependent Cardiac Remodeling in Mice Deficient in Guanylyl Cyclase A, a Receptor for Atrial and Brain Natriuretic Peptides , 2005, Circulation.

[25]  C. Molina,et al.  Functional Role of Phosphodiesterase 3 in Cardiomyocyte Apoptosis: Implication in Heart Failure , 2005, Circulation.

[26]  P. Fisher,et al.  Phosphodiesterase-5 Inhibition With Sildenafil Attenuates Cardiomyocyte Apoptosis and Left Ventricular Dysfunction in a Chronic Model of Doxorubicin Cardiotoxicity , 2005, Circulation.

[27]  Anindita Das,et al.  Phosphodiesterase-5 Inhibitor Sildenafil Preconditions Adult Cardiac Myocytes against Necrosis and Apoptosis , 2005, Journal of Biological Chemistry.

[28]  H. E. Marshall,et al.  Protein S-nitrosylation: purview and parameters , 2005, Nature Reviews Molecular Cell Biology.

[29]  D. Kass,et al.  Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy , 2005, Nature Medicine.

[30]  M. Zaccolo,et al.  cGMP Catabolism by Phosphodiesterase 5A Regulates Cardiac Adrenergic Stimulation by NOS3-Dependent Mechanism , 2004, Circulation research.

[31]  Chen Yan,et al.  Angiotensin II increases phosphodiesterase 5A expression in vascular smooth muscle cells: a mechanism by which angiotensin II antagonizes cGMP signaling. , 2005, Journal of molecular and cellular cardiology.

[32]  D. Kass,et al.  Sildenafil inhibits beta-adrenergic-stimulated cardiac contractility in humans. , 2005, Circulation.

[33]  J. Liao,et al.  Inhibition of Rho-Kinase Leads to Rapid Activation of Phosphatidylinositol 3-Kinase/Protein Kinase Akt and Cardiovascular Protection , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[34]  T. Bivalacqua,et al.  Effect of combination endothelial nitric oxide synthase gene therapy and sildenafil on erectile function in diabetic rats , 2004, International Journal of Impotence Research.

[35]  J. Kotera,et al.  Allosteric sites of phosphodiesterase-5 sequester cyclic GMP. , 2004, Frontiers in bioscience : a journal and virtual library.

[36]  C. Deschepper,et al.  Expression of Constitutively Active Guanylate Cyclase in Cardiomyocytes Inhibits the Hypertrophic Effects of Isoproterenol and Aortic Constriction on Mouse Hearts* , 2003, Journal of Biological Chemistry.

[37]  J. Balligand,et al.  Nitric Oxide and Cardiac Function: Ten Years After, and Continuing , 2003, Circulation research.

[38]  M. Billah,et al.  Identification and characterization of a new human type 9 cGMP-specific phosphodiesterase splice variant (PDE9A5). Differential tissue distribution and subcellular localization of PDE9A variants. , 2003, Gene.

[39]  J. Beavo,et al.  Regulation of Nitric Oxide–Sensitive Guanylyl Cyclase Cyclic GMP Phosphodiesterases and Regulation of Smooth Muscle Function Structure, Regulation, and Function of Membrane Guanylyl Cyclase Receptors, With a Focus on GC-A Cyclic GMP–Dependent Protein Kinases and the Cardiovascular System: Insights F , 2003 .

[40]  R. Kloner,et al.  Therapeutic potential of phosphodiesterase 5 inhibition for cardiovascular disease. , 2003, Circulation.

[41]  K. Wennerberg,et al.  Serine Phosphorylation Negatively Regulates RhoA in Vivo* , 2003, Journal of Biological Chemistry.

[42]  H. Schäfers,et al.  Effects of Sildenafil (Viagra) on Human Myocardial Contractility, In Vitro Arrhythmias, and Tension of Internal Mammaria Arteries and Saphenous Veins , 2003, Journal of cardiovascular pharmacology.

[43]  Michael D. Schneider,et al.  Pressure-independent cardiac hypertrophy in mice with cardiomyocyte-restricted inactivation of the atrial natriuretic peptide receptor guanylyl cyclase-A. , 2003, The Journal of clinical investigation.

[44]  R. Bache,et al.  Effect of PDE5 inhibition on coronary hemodynamics in pacing-induced heart failure. , 2003, American journal of physiology. Heart and circulatory physiology.

[45]  F. Romano,et al.  Inhibition of cyclic GMP hydrolysis with zaprinast reduces basal and cyclic AMP‐elevated L‐type calcium current in guinea‐pig ventricular myocytes , 2003, British journal of pharmacology.

[46]  J. Beavo,et al.  PDE5 is converted to an activated state upon cGMP binding to the GAF A domain , 2003, The EMBO journal.

[47]  R. Ritchie,et al.  Antihypertrophic actions of the natriuretic peptides in adult rat cardiomyocytes: importance of cyclic GMP. , 2003, Cardiovascular research.

[48]  J. Corbin,et al.  Sildenafil citrate does not affect cardiac contractility in human or dog heart , 2003, Current medical research and opinion.

[49]  K. Omori,et al.  cGMP-Phosphodiesterase Activity Is Up-regulated in Response to Pressure Overload of Rat Ventricles , 2003, Bioscience, biotechnology, and biochemistry.

[50]  H. Drexler,et al.  Inhibition of calcineurin-NFAT hypertrophy signaling by cGMP-dependent protein kinase type I in cardiac myocytes , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[51]  Å. Gustafsson,et al.  Attenuation of cAMP accumulation in adult rat cardiac fibroblasts by IL-1beta and NO: role of cGMP-stimulated PDE2. , 2002, American journal of physiology. Cell physiology.

[52]  D. Okada,et al.  Allosteric activation of cGMP-specific, cGMP-binding phosphodiesterase (PDE5) by cGMP. , 2002, Biochemistry.

[53]  A. Shah,et al.  Role of cyclic GMP‐dependent protein kinase in the contractile response to exogenous nitric oxide in rat cardiac myocytes , 2002, The Journal of physiology.

[54]  C. Trautwein,et al.  Gene Transfer of cGMP-Dependent Protein Kinase I Enhances the Antihypertrophic Effects of Nitric Oxide in Cardiomyocytes , 2002, Hypertension.

[55]  Joao A. C. Lima,et al.  Nitric oxide regulates the heart by spatial confinement of nitric oxide synthase isoforms , 2002, Nature.

[56]  J. Beavo,et al.  Upregulation of Phosphodiesterase 1A1 Expression Is Associated With the Development of Nitrate Tolerance , 2001, Circulation.

[57]  A. Friebe,et al.  Rapid nitric oxide–induced desensitization of the cGMP response is caused by increased activity of phosphodiesterase type 5 paralleled by phosphorylation of the enzyme , 2001, The Journal of cell biology.

[58]  T. Lincoln,et al.  Invited review: cGMP-dependent protein kinase signaling mechanisms in smooth muscle: from the regulation of tone to gene expression. , 2001, Journal of applied physiology.

[59]  D. Kass,et al.  Cardiac phosphodiesterase 5 (cGMP‐specific) modulates β‐adrenergic signaling in vivo and is down‐regulated in heart failure , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[60]  N. Morrell,et al.  Sildenafil Inhibits Hypoxia-Induced Pulmonary Hypertension , 2001, Circulation.

[61]  J. Corbin,et al.  Allosteric sites of phosphodiesterase-5 (PDE5) , 2001 .

[62]  R. Fischmeister,et al.  Cyclic GMP regulation of the L‐type Ca2+ channel current in human atrial myocytes , 2001, The Journal of physiology.

[63]  J. Knowles,et al.  Pressure-independent enhancement of cardiac hypertrophy in natriuretic peptide receptor A-deficient mice. , 2001, The Journal of clinical investigation.

[64]  D. Garbers,et al.  A genetic model provides evidence that the receptor for atrial natriuretic peptide (guanylyl cyclase-A) inhibits cardiac ventricular myocyte hypertrophy , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[65]  T. Lue,et al.  Identification and regulation of human PDE5A gene promoter. , 2001, Biochemical and biophysical research communications.

[66]  T. Lue,et al.  Regulation of human PDE5A2 intronic promoter by cAMP and cGMP: identification of a critical Sp1-binding site. , 2001, Biochemical and biophysical research communications.

[67]  H. Inoue,et al.  Pharmacological profile of T-1032, a novel specific phosphodiesterase type 5 inhibitor, in isolated rat aorta and rabbit corpus cavernosum. , 2001, European journal of pharmacology.

[68]  J. Corbin,et al.  Allosteric sites of phosphodiesterase-5 (PDE5). A potential role in negative feedback regulation of cGMP signaling in corpus cavernosum. , 2001, European journal of biochemistry.

[69]  W. Zapol,et al.  Sildenafil Is a Pulmonary Vasodilator in Awake Lambs with Acute Pulmonary Hypertension , 2000, Anesthesiology.

[70]  J. Corbin,et al.  Phosphorylation of phosphodiesterase-5 by cyclic nucleotide-dependent protein kinase alters its catalytic and allosteric cGMP-binding activities. , 2000, European journal of biochemistry.

[71]  K. Omori,et al.  A Novel Interaction of cGMP-dependent Protein Kinase I with Troponin T* , 1999, The Journal of Biological Chemistry.

[72]  E. Lakatta,et al.  Activation of distinct cAMP-dependent and cGMP-dependent pathways by nitric oxide in cardiac myocytes. , 1999, Circulation research.

[73]  J. Corbin,et al.  Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. , 1999, The American journal of cardiology.

[74]  G. Kojda,et al.  Regulation of basal myocardial function by NO. , 1999, Cardiovascular research.

[75]  R. Fischmeister,et al.  Muscarinic and beta-adrenergic regulation of heart rate, force of contraction and calcium current is preserved in mice lacking endothelial nitric oxide synthase. , 1999, Nature medicine.

[76]  K. Ferguson,et al.  Isolation and characterization of cDNAs encoding PDE5A, a human cGMP-binding, cGMP-specific 3',5'-cyclic nucleotide phosphodiesterase. , 1998, Gene.

[77]  S. Phillips,et al.  Molecular cloning and expression of human cGMP-binding cGMP-specific phosphodiesterase (PDE5). , 1998, Biochemical and biophysical research communications.

[78]  V. Coghlan,et al.  Identification of cGMP-dependent protein kinase anchoring proteins (GKAPs). , 1998, Biochemical and biophysical research communications.

[79]  N. Takahashi,et al.  Nitric oxide, atrial natriuretic peptide, and cyclic GMP inhibit the growth-promoting effects of norepinephrine in cardiac myocytes and fibroblasts. , 1998, The Journal of clinical investigation.

[80]  J. Corbin,et al.  Binding of cGMP to both allosteric sites of cGMP-binding cGMP-specific phosphodiesterase (PDE5) is required for its phosphorylation. , 1998, The Biochemical journal.

[81]  W. K. Sonnenburg,et al.  Identification, quantitation, and cellular localization of PDE1 calmodulin-stimulated cyclic nucleotide phosphodiesterases. , 1998, Methods.

[82]  E. Krebs,et al.  Calmodulin-stimulated cyclic nucleotide phosphodiesterase (PDE1C) is induced in human arterial smooth muscle cells of the synthetic, proliferative phenotype. , 1997, The Journal of clinical investigation.

[83]  M. Böhm,et al.  Acute effects of nitric oxide and cyclic GMP on human myocardial contractility. , 1997, The Journal of pharmacology and experimental therapeutics.

[84]  L. Wang,et al.  Characterization of two recombinant PDE3 (cGMP-inhibited cyclic nucleotide phosphodiesterase) isoforms, RcGIP1 and HcGIP2, expressed in NIH 3006 murine fibroblasts and Sf9 insect cells. , 1996, Biochemistry.

[85]  W. K. Sonnenburg,et al.  Identification of Inhibitory and Calmodulin-binding Domains of the PDE1A1 and PDE1A2 Calmodulin-stimulated Cyclic Nucleotide Phosphodiesterases (*) , 1995, The Journal of Biological Chemistry.

[86]  M. Creager,et al.  Nitric Oxide Inhibits the Positive Inotropic Response to β-Adrenergic Stimulation in Humans With Left Ventricular Dysfunction , 1995 .

[87]  M. Kirstein,et al.  Nitric oxide regulates the calcium current in isolated human atrial myocytes. , 1995, The Journal of clinical investigation.

[88]  M. Creager,et al.  Nitric oxide inhibits the positive inotropic response to beta-adrenergic stimulation in humans with left ventricular dysfunction. , 1995, Circulation.

[89]  E. Lakatta,et al.  8-bromo-cGMP reduces the myofilament response to Ca2+ in intact cardiac myocytes. , 1994, Circulation research.

[90]  J. Corbin,et al.  Substrate- and kinase-directed regulation of phosphorylation of a cGMP-binding phosphodiesterase by cGMP. , 1990, The Journal of biological chemistry.

[91]  M. Hagiwara,et al.  Effects of vinpocetine on cyclic nucleotide metabolism in vascular smooth muscle. , 1984, Biochemical pharmacology.